- Preliminary findings confirm that dual therapy rilpivirine (RPV; Edurant) plus booster darunavir (DRVb) is an effective treatment strategy for patients with advanced HIV and extended antiretroviral therapy (ART) exposure.
Why this matters
- Consider RPV+DRVb as an alternative to triple therapy in both stable, virologically suppressed and patients with low CD4 nadir, viral failure (VF), and previous nonsuppressive ART.
- 161 patients, median time since HIV diagnosis 17 (interquartile range [IQR], 10-23) years, median ART receipt 14 (IQR, 6-18) years.
- 25.5% (41) had unsuppressed viremia (50-1000 copies/mL), 36.6% (59) had previous VF at baseline.
- At week 24, 87.6% (141/161) of intent-to-treat (ITT) on RPV+DRVb showed no VF; 17 discontinued.
- 94.6% (141/149) comprised on-treatment (OT) population completed study with no VF criteria signs.
- At week 24, 82.6% (133/161), 89.3% (133/149) of ITT, OT patients, respectively, had VF
- Previous failure with darunavir did not increase likelihood for VF with dual therapy: 13.3% (4/30) vs 5.5% (1/18); P=.348.
- No serious adverse events observed.
- Retrospective observational, multicenter cohort analyzing RPV+DRVb effectiveness in advanced HIV infections.
- Funding: Janssen-Cilag Spain.
- Inclusion bias.
- Short follow-up.